Biomarkers in heart failure management

Current Opinion in Cardiology

Volumn 23, Issue 2, 2008, Pages 127-133

  Isaac, Debra L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Biomarkers; Heart failure; Natriuretic peptides

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ANEMIA; CARDIAC RESYNCHRONIZATION THERAPY; CORONARY ARTERY BYPASS GRAFT; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; ECHOCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODIALYSIS; HEMODYNAMICS; HUMAN; ISCHEMIC HEART DISEASE; MITRAL VALVE REGURGITATION; OBESITY; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVASCULARIZATION; REVIEW; SEPSIS; STROKE; SYSTOLIC DYSFUNCTION;

BIOLOGICAL MARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS;

EID: 40049100464     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f43039     Document Type: Review

References (86)

1. Buttner J. Reference materials and reference methods in laboratory medicine: a challenge to international cooperation. Eur J Clin Chem Clin Biochem 1994; 32:571-577.
2. Hama N, Itoh H, Shirakami G. Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 1995; 92:1558-1564.
3. Balion C, Santaguida P, Hill S, et al. Testing for BNP and NT-proBNP in the diagnosis and prognosis of heart failure. Evidence report/technology assessment no. 142. Prepared by the McMaster University Evidence-based Practice Center under contract 290-02-0020. AHRQ publ. no. 06-E014. Rockville: Agency for Healthcare Research and Quality; 2006. An extensive systematic review of BNP and NT-pro-BNP in the diagnosis, prognosis and treatment of heart failure. This review examines in detail the determinants of BNP and NT-pro-BNP, the clinical performance characterization of these markers, and their ability to add independent diagnostic, prognostic, screening and treatment monitoring value.
4. Morello A, Lloyd-Jones DM, Chae CU, et al. Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Am Heart J 2007; 153:90-97.
5. Galema TW, Yap SC, Geleijnse ML, et al. Early detection of left ventricular dysfunction by Doppler tissue imaging and N-terminal pro-B-type natriuretic peptide in patients with symptomatic severe aortic stenosis. J Am Soc Echocardiogr 2007. [Epub ahead of print]
6. Wagner JA, Störk S, Weidemann F, et al. Natriuretic peptides and myocardial oxygen supply-to-demand ratio in patients with aortic stenosis. Eur J Clin Invest 2007; 37:463-471.
7. Arikan S, Tuzcu A, Gokalp D, et al. Hyperthyroidism may affect serum N-terminal pro-B-type natriuretic peptide levels independently of cardiac dysfunction. Clin Endocrinol 2007; 67:202-207.
8. Navarro Estrada JL, Rubinstein F, Bahit MC, et al., PACS Investigators. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes. Am Heart J 2006; 151:1093.e1-1093.e7.
9. Schoen SP, Zimmermann T, Kittner T, et al. NT-proBNP correlates with right heart haemodynamic parameters and volumes in patients with atrial septal defects. Eur J Heart Fail 2007; 9:660-666.
10. Blyth KG, Groenning BA, Mark PB, et al. NT-proBNP can be used to detect right ventricular systolic dysfunction in pulmonary hypertension. Eur Respir J 2007; 29:737-744.
11. Iltumur K, Yavavli A, Apak I, et al. Elevated plasma N-terminal pro-brain natriuretic peptide levels in acute ischemic stroke. Am Heart J 2006; 151: 1115-1122.
12. Kim JY, Lee EY, Jee JH, et al. N-terminal pro-brain natriuretic peptide (NT-proBNP) in Type 2 diabetes with left ventricular dysfunction. Diabetes Res Clin Pract 2007; 77:S238-S242.
13. Muscari A, Berzigotti A, Bianchi G, et al. Noncardiac determinants of NT-proBNP levels in the elderly: relevance of haematocrit and hepatic steatosis. Eur J Heart Fail 2006; 8:468-476.
14. Fried I, Bar-Oz B, Algur N, et al. Comparison of N-terminal pro-B-type natriuretic peptide levels in critically ill children with sepsis versus acute left ventricular dysfunction. Pediatrics 2006; 118:e1165-e1168.
15. Azevedo A, Bettencourt P, Barros H. Demographic, clinical and echocardiographic determinants of B-type natriuretic peptide plasma concentration. A population based study. Rev Port Cardiol 2007; 26:105-113.
16. Luchner A, Hengstenberg C, Löwel H, et al. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005; 46:118-123.
17. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005; 46:610-620.
18. Austin WJ, Bhalla V, Hernandez-Arce I, et al. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006; 126:506-512.
19. deFilippi CR, Seliger SL, Maynard S, Christenson RH. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin Chem 2007; 53:1511-1519.
20. Bruch C, Reinecke H, Stypmann J, et al. N-terminal pro-brain natriuretic peptide, kidney disease and outcome in patients with chronic heart failure. J Heart Lung Transplant 2006; 25:1135-1141.
21. Anwaruddin A, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. J Am Coll Cardiol 2006; 47:91-97.
22. Zeng C, Wei T, Jin L, Wang L. Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J 2006; 36:552-557.
23. Racek J, Kralova H, Trefil L, et al. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006; 103: 162-172.
24. Redfield MM, Rodeheffer RJ, Jacobsen SJ, et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 2002; 40:976-982.
25. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5:599-606.
26. Arnold JMO, Howlett JG, Dorian P, et al. Canadian Cardiovascular Society Consensus Conference recommendations on heart failure update 2007: prevention, management during intercurrent illness or acute decompensation, and use of biomarkers. Can J Cardiol 2007; 23:21-45. Canadian consensus guidelines including the recommendations for use of biomarkers in heart failure.
27. Emdin M, Passino C, Del Ry S, et al. Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. Clin Chem Lab Med 2003; 41:686-692.
28. Khush KK, Gerber IL, Mckeown B, et al. Obese patients have lower B-type natriuretic peptide levels compared with nonobese. Congest Heart Fail 2006; 12:85-90.
29. Taylor JA, Christenson RH, Rao K, et al. B-type natriuretic peptide and N-terminal pro B-type natriuretic peptide are depressed in obesity despite higher left ventricular end diastolic pressures. Am Heart J 2006; 152:1071-1076.
30. Yoshimura M, Mizuno Y, Nakayama M, et al. B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 2002; 112:716-720.
31. Latini R, Masson S, Anand I, et al., for the Val-HeFT Investigators. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: The Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106:2454-2458.
32. Rousseau MF, Gurné O, Duprez D, et al. Beneficial neurohormonal profile of spironolactone in severe congestive heart failure: Results from the RALES neurohormonal substudy. J Am Coll Cardiol 2002; 40:1596-1601.
33. Fung JWH, Yu CM, Yip G, et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 2003; 92: 406-410.
34. Mehra MR, Uber PA, Walther D, et al. Gene expression profiles and B-type natriuretic peptide elevation in heart transplantation: more than a hemodynamic marker. Circulation 2006; 114:I21-I26.
35. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
36. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from the Breathing Not Properly (BNP) multinational study. Circulation 2002; 106: 416-422.
37. Januzzi JL, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005; 95:948-954.
38. Clerico A, Emdin M. Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem 2004; 50:33-50.
39. Tschöpe C, Kasner M, Westermann D, et al. The role of NT-proBNP in the diagnosis of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J 2005; 26:2277-2284.
40. Iwanaga Y, Nishi I, Furuichi S, et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J Am Coll Cardiol 2006; 47:742-748.
41. Horwich TB, Hamilton MA, Fonarow GC. B-type natriuretic peptide levels in obese patients with advanced heart failure. J Am Coll Cardiol 2006; 47:85-90.
42. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of Chronic Heart Failure: full text (update 2005). The Task Force for the Diagnosis and Treatment of CHF of the European Society of Cardiology. Eur Heart J 2005; 26:2472.
43. Hunt SA, Abraham WT, ChinMH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2005; 112:e154-e235.
44. Zaphirioru A, Robb S, Muray-Thoma T, et al. The diagnostic accuracy of plasma BNP and NT-proBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 2005; 7:537-541.
45. Gardner RS, Ozalp F, Murday AJ, et al. N-terminal pro-brain natriuretic peptide, a new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003; 24:1735-1743.
46. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005; 330:625-636.
47. Christ M, Laule-Kilian K, Hochholzer W, et al. Gender-specific risk stratification with B-type natriuretic peptide levels in patients with acute dyspnea. J Am Coll Cardiol 2006; 48:1808-1812.
48. Van Kimmenade RR, Pinto YM, Bayes-Genis A, et al. Usefulness of intermediate amino-terminal pro-brain natriuretic peptide concentrations for diagnosis and prognosis of acute heart failure. Am J Cardiol 2006; 98:386-390.
49. Yusoff R, Clayton N, Keevil B, et al. Utility of plasma N-terminal brain natriuretic peptide as a marker of functional capacity in patients with chronic severe mitral regurgitation. Am J Cardiol 2006; 97:1498-1501.
50. Feringa HH, Poldermans D, Klein P, et al. Plasma natriuretic peptide levels reflect changes in heart failure symptoms, left ventricular size and function after surgical mitral valve repair. Int J Cardiovasc Imaging 2007; 23:159-165.
51. Cerrahoglu M, Iskesen I, Tekin C, et al. N-terminal ProBNP levels can predict cardiac failure after cardiac surgery. Circ J 2007; 71:79-83.
52. Shelton RJ, Clark AL, Goode K, et al. The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation. Eur Heart J 2006; 27:2353-2361.
53. Corell P, Gustafsson F, Kistorp C, et al. Effect of atrial fibrillation on plasma NT-proBNP in chronic heart failure. Int J Cardiol 2007; 117:395-402.
54. Ahmed W, Zafar S, Alam AY, et al. Plasma levels of B-type natriuretic peptide in patients with unstable angina pectoris or acute myocardial infarction: prognostic significance and therapeutic implications. Angiology 2007; 58:269-274.
55. Yu CM, Fung JW, Zhang Q, et al. Improvement of serum NT-ProBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail 2005; 11 (5 Suppl): S42-S46.
56. Price JF, Thomas AK, Grenier M, et al. B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 2006; 114:1063-1069.
57. Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001; 37:386-391.
58. Klein G, Lissel C, Fuchs AC, et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-study. Europace 2006; 8:618-624.
59. Manios EG, Kallergis EM, Kanoupakis EM, et al. Amino-terminal pro-brain natriuretic peptide predicts ventricular arrhythmogenesis in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillators. Chest 2005; 128:2604-2610.
60. Tangc WHW, Francis GS, Morrow DA, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 2007; 116:e99-e109. Review and recommendations for the use of biomarkers in the diagnosis, screening, risk stratification and management of heart failure.
61. Heart Protection Study Collaborative Group. N-terminal pro-B-type natriuretic peptide, vascular disease risk and cholesterol reduction among 20,536 patients in the MRC/BHF heart protection study. J Am Coll Cardiol 2007; 49:311-319.
62. McKie PM, Rodeheffer RJ, Cataliotti A, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension 2006; 47:874-880.
63. Olsen MH, Hansen TW, Christensen MK, et al. N-terminal pro-brain natriuretic peptide, but not high sensitivity C-reactive protein, improves cardiovascular risk prediction in the general population. Eur Heart J 2007; 28:1374-1381.
64. Costello-Boerrigter LC, Boerrigter G, Redfield MM, et al. Amino-terminal pro-B-type natriuretic peptide in the general community: determinants and detection of the left ventricular dysfunction. J Am Coll Cardiol 2006; 47: 345-353.
65. Abhayaratna WP, Marwick TH, Becker NG, et al. Population-based detection of systolic and diastolic dysfunction with amino-terminal pro-B-type natriuretic peptide. Am Heart J 2006; 152:941-948.
66. Dernellis J, Panaretou M. Assessment of cardiac risk before noncardiac surgery: brain natriuretic peptide in 1590 patients. Heart 2006; 92:1645-1650.
67. Struthers A, Lang C. The potential to improve primary prevention in the future by using BNP/N-BNP as an indicator of silent 'pancardiac' target organ damage: BNP/N-BNP could become for the heart what microalbuminuria is for the kidney. Eur Heart J 2007; 28:1678-1682.
68. Siebert U, Januzzi JL, Beinfeld MT, et al. Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 2006; 98:800-805.
69. Mueller C, Scholer A, Laule-Kilian K, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004; 350:647-654.
70. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355:1126-1130.
71. Breidthardt T, Laule K, Strohmeyer A-H, et al. Medical and economic long-term effects of B-type natriuretic peptide testing in patients with acute dyspnea. Clin Chem 2007; 53:1415-1422.
72. Jourdain P, Jondeau G, Funck K, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol 2007; 49:1733-1739.
73. Shah MR, Califf RM, Nohria A, et al. A randomized pilot trial of BNP-guided therapy in pts with advanced heart failure [abstract]. AHA Scientific Sessions. Chicago 2006; 2554.
74. Moe GW, Howlett J, Januzzi JL, Zowall H. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007; 115:3103-3110.
75. Lainchbury JG, Troughton RW, Frampton CM, et al. NT-proBNP guided drug treatment for chronic heart failure: design and methods in the BATTLE-SCARRED trial. Eur J Heart Fail 2006; 8:532-538.
76. Brunner-La Rocca HP, Buser PT, Schindler R, et al., TIME-CHF-Investigators. Management of elderly patients with congestive heart failure - design of the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 2006; 151:949-955.
77. Maisel A, Hollander JE, Guss D, et al., for the Rapid Emergency Department Heart Failure Outpatient Trial investigators. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44:1328-1333.
78. Apple FS, Wu AHB, Jaffe AS, et al. National Academy of Clinical Biochemistry and IFCC Committee for Standardization of Markers of Cardiac Damage Laboratory Medicine Practice Guidelines: analytical issues for biomarkers of heart failure. Circulation 2007; 116:e95-e98. Review of the methodological and analytical issues with regard to the use of biomarkers in heart failure.
79. Lam CS, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol 2007; 49:1193-1202.
80. Apple FS, Panteghini M, Raykilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005; 51:486-493.
81. la-Kopsala M, Magga J, Peuhkurinen K, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004; 50:1576-1588.
82. Januzzu JL, Ellinor PT, Sharma UC, et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 2006; 48:1217-1224.
83. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003; 108:833-838.
84. Kalra PR, Clague JR, Bolger AP, et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003; 107:571-573.
85. Gegenhuber A, Struck J, Poelz W, et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006; 52:827-831.
86. Lee DS, Vasan RS. Novel markers for heart failure diagnosis and prognosis. Curr Opin Cardiol 2005; 20:201-210.